What the Biden Administration Means for Drug Pricing, Coverage and Reimbursement

Prior to the COVID-19 pandemic, one of the most widely discussed issues related to pharmaceuticals was pricing. It was the subject of the Trump Administration's "American Patients First:  The Trump Administration Blueprint to Lower Drug Prices and Reduce Out-of-Pocket-Costs" as well as numerous Executive Orders and agency rules. Drug prices remain part of the national discussion under the Biden Administration, which favors federal government negotiation of prices under Medicare Part D, greater access to generic drugs and potential importation. Likewise, several bills in Congress on both sides of the aisle had significant momentum pre-COVID and are likely to resurface.

This course, presented by Stephanie Trunk, Partner at Arent Fox LLP, discusses the status of Trump era efforts aimed at reforming drug pricing, coverage and reimbursement and contemplates future regulation and policy under the Biden Administration and new Congress.   

1. Discuss the status of Trump Administration rules related Medicaid, Medicare Part D and the 340B Administrative Dispute Resolution process, many of which has been "paused" by the Biden Administration or are the subject of ongoing lawsuits
2. Review altered pricing and coverage policies given the COVID pandemic, discuss their future after COVID and explore drug related "pay fors" in various COVID relief packages
3. Consider views on drug pricing and reimbursement reform under the Biden Administration/the new Congress and review ideas in various bills such as H.R. 3- Lower Drug Costs Now Act- and S. 2542- Prescription Drug Pricing Reduction Act